CZI Pledges Billions More Dollars in Science Funding

Priscilla Chan and Mark Zuckerberg are dedicating a further $3.4 billion to biomedical and human health research on top of $3 billion invested several years ago, the organization announced this week.

Written byCatherine Offord
| 2 min read
Cofounders and co-CEOs of the Chan Zuckerberg Initiative, Mark Zuckerberg and Priscilla Chan
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Aphilanthropic organization established by Facebook CEO Mark Zuckerberg and his wife Priscilla Chan will invest $3.4 billion in research to help cure, prevent, and manage human disease, according to a press statement released on Tuesday (December 7).

The money from the Chan Zuckerberg Initiative (CZI), which was founded in 2015, follows an earlier $3 billion investment and will be used to support scientific research over the next 10–15 years. Plans include establishing new research centers—such as an artificial intelligence institute at Harvard University and a biomedical imaging center with a yet-to-be determined location—as well as supporting collaborative projects such as the CZ Biohub Network, which will connect researchers working on disease mechanisms and therapies.

“Biomedical science and technology development hold tremendous promise to advance human health and treat disease,” Chan, a former pediatrician, says in the press statement. “Working as partners with scientists, patients, and open source communities, we’ve learned ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies